A new manuscript from the IGNITE Pragmatic Trials Network has been published in JAMA Network Open, describing the primary results of the GUARDD-US study. GUARDD-US is a randomized controlled trial examining the impact of returning APOL1 genetic risk results to ...
Personalized Therapeutics: Clinical Reality and Future Challenges Thursday, February 15 | 9 a.m. ET | Virtual Speaker: George P. Patrinos Dr. Patrinos is a professor of pharmacogenomics and pharmaceutical biotechnology in […]
Population Screening for Hereditary Hemochromatosis More than a Quarter Century After Gene Discovery – Current Status and the Path Forward Thursday, February 15 | 1-2 p.m. ET | Virtual Speakers: […]
GMKB